Emergent Biosolutions
EBS
EBS
244 hedge funds and large institutions have $2.35B invested in Emergent Biosolutions in 2019 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 89 increasing their positions, 90 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 90
2.1% less ownership
Funds ownership: 89.26% → 87.16% (-2.1%)
87% less call options, than puts
Call options by funds: $371K | Put options by funds: $2.75M
Holders
244
Holding in Top 10
2
Calls
$371K
Puts
$2.75M
Top Buyers
1 | +$19.6M | |
2 | +$17M | |
3 | +$11.4M | |
4 |
Neuberger Berman Group
New York
|
+$11.2M |
5 |
TCM
Tygh Capital Management
Portland,
Oregon
|
+$10.6M |
Top Sellers
1 | -$37.4M | |
2 | -$25.1M | |
3 | -$19.1M | |
4 |
![]()
Fidelity Investments
Boston,
Massachusetts
|
-$12.1M |
5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$10.7M |